Comparative analysis of lipid composition of normal and acute-phase high density lipoproteins.
In the acute-phase response and in diseases with prolonged acute phases, normal HDL (NHDL) is converted into acute-phase HDL (APHDL) and becomes proinflammatory and unable to protect LDL against oxidative modification. Earlier work had demonstrated that these changes are associated with alterations in apolipoprotein composition and enzymatic activity of APHDL, but the effect of the acute-phase condition on the lipid composition of APHDL had remained obscure. The present study shows marked quantitative differences in lipid composition between NHDL and APHDL. Specifically, APHDL contained 25% less total lipid per milligram of protein. Up to 50% of cholesteryl ester in the lipid core of APHDL was replaced by triacylglycerol; however, the total phospholipid/total neutral lipid ratios were the same as in NHDL, both lipoproteins giving similar calculated lipid core radii. Furthermore, the phosphatidylcholine/sphingomyelin ratio in APHDL was nearly double that in NHDL, indicating a relative loss of sphingomyelin. A decrease was also seen in diacyl and alkenylacyl glycerophosphatidylethanolamine as well as in phosphatidylinositol of APHDL when compared with NHDL. APHDL contained proportionally more saturated and less polyunsaturated and isoprostane-containing species of phosphatidylcholine, as well as more saturated than unsaturated cholesteryl esters. APHDL also contained significantly more free fatty acids, lysophosphatidylcholine, and free cholesterol. These changes in the lipid composition of HDL are consistent with the alterations in the apoprotein composition and enzymatic activity of APHDL and indicate proinflammatory and proatherogenic roles for APHDL.
Pruzanski
W
W
Inflammation Research Group, University of Toronto, Canada.
Stefanski
E
E
de Beer
F C
FC
de Beer
M C
MC
Ravandi
A
A
Kuksis
A
A
D000209:Acute-Phase Proteins / Q000737:chemistry*; D000210:Acute-Phase Reaction / Q000097:blood*; D016632:Apolipoprotein A-I / Q000032:analysis; D001053:Apolipoproteins / Q000032:analysis; D001161:Arteriosclerosis / Q000209:etiology; D005227:Fatty Acids / Q000032:analysis; D006801:Humans; D007249:Inflammation / Q000209:etiology; D008055:Lipids / Q000737:chemistry*; D008075:Lipoproteins, HDL / Q000737:chemistry*; D010316:Particle Size; D010743:Phospholipids / Q000032:analysis; D000685:Serum Amyloid A Protein / Q000032:analysis; D014280:Triglycerides / Q000032:analysis
D000209:Acute-Phase Proteins; D016632:Apolipoprotein A-I; D001053:Apolipoproteins; D005227:Fatty Acids; D008055:Lipids; D008075:Lipoproteins, HDL; D010743:Phospholipids; D000685:Serum Amyloid A Protein; D014280:Triglycerides